<DOC>
	<DOCNO>NCT01011751</DOCNO>
	<brief_summary>The purpose study compare efficacy three drug ( cyproterone acetate , medroxyprogesterone acetate venlafaxine ) treatment hot flush cause leuprorelin LP 11.25 milligram ( mg ) participant suffer prostate cancer .</brief_summary>
	<brief_title>Treatment Hot Flushes Caused Leuprorelin 11.25 mg Prostate Adenocarcinoma</brief_title>
	<detailed_description>Three drug test study : cyproterone acetate , medroxyprogesterone acetate venlafaxine . Cyproterone acetate , medroxyprogesterone acetate venlafaxine test treat men suffer hot flush due androgen suppression treatment prostate cancer . This study look frequency severity hot flush cause leuprorelin participant take cyproterone acetate , medroxyprogesterone acetate venlafaxine . The study randomize approximately 311 participant . All participant receive 2 injection leuprorelin 11.35 mg Months 0 3 along flutamide tablet first month treatment prevent flare-up . After 6 month , eligible participant receive third injection leuprorelin randomly assign one three treatment groups—which remain undisclosed participant study doctor study ( unless urgent medical need ) : - Cyproterone acetate ( Androcur® 50 mg ) - Medroxyprogesterone acetate ( Gestoral® 10 mg ) - Venlafaxine ( Effexor® LP 37.5 mg ) All participant ask take 2 capsule morning 1 capsule even 10 week . All participant ask complete self-evaluation hot-flushes ( HF ) questionnaire daily 12 week start treatment hot flush . This multi-center trial conduct France . The overall time participate study approximately 9 month . Participants make 5 visit clinic study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<criteria>Patient histologically proven prostatic adenocarcinoma . Patient gonadotropin release hormone ( GnRH ) agonist treatment duration least 1 year . Karnofsky index great equal ( &gt; = ) 70 % . Patient , clearly inform , give write consent participate study . Patient include therapeutic trial 3 month precede inclusion visit . Prescription agonist plan context neoadjuvant hormonotherapy . Patient symptomatic bone metastasis . Patient already treat hormonotherapy prostate cancer receive hormonal treatment GnRH agonist cancer ( apart palliative care flareup antiandrogens ) . Patient unable understand information regard study provide , give consent refuse sign informed consent sheet . Patient risk follow could guarantee within condition stipulate protocol unable complete selfevaluation questionnaire . Diabetic , patient severe progressive disease : kidney , liver , cardiovascular ( especially high uncontrolled BP ) , psychiatric . Has Thromboembolic history concomitant thromboembolic disease . Patient hepatocellular insufficiency hepatic cytolysis ( serum glutamic oxaloacetic transaminase / serum glutamic pyruvate transaminase [ SGOT/SGPT ] &gt; 3 time laboratory normal range ) . Patient contraindication one study drug . Patient receive corticotherapy concomitant prescription nonselective monoamine oxidase inhibitor ( MAOI ) , serotonin reuptake inhibitor , clonidine , gabapentine , veripride , tibolone betaalanine . Patient undergoing medical treatment depressive phase treat previous 2 year inclusion . Patient history congenital galactosemy , poor absorption glucose galactose syndrome even lactase deficiency . Patient another cancer 5 previous year exclude basocellular epithelioma situ carcinoma .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>